Respiratory syncytial virus infectious disease

This study tests an experimental vaccine called AZD6489 in adults aged 60 and older. The vaccine is designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections in older people. Participants receive a single injection of eit…

This study tests a single dose of an experimental RSV vaccine in Chinese adults aged 18 to 59 who have health conditions that raise their risk for severe RSV disease. Researchers will compare their immune response to that of older adults (60+) from a previous study. The trial als…

This study looks at how well an RSV vaccine works and how safe it is in adults who have had a lung or kidney transplant. About 184 participants will receive the vaccine to see if their immune response lasts and if a booster dose is safe. The goal is to help protect transplant rec…

This study looks at the best timing for a booster shot of the RSV vaccine in adults aged 60 and older. It will follow over 10,000 participants for up to 5 years to see how long protection lasts and whether a second dose is needed. The goal is to help prevent serious RSV infection…

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses of the vaccine at dif…

This early-stage trial is testing two mRNA vaccines in children aged 5 months to under 24 months. One vaccine targets RSV alone, and the other targets both RSV and hMPV. The main goals are to check safety and see how well the vaccines trigger an immune response. About 186 childre…

This study examines how well the ABRYSVO vaccine works when given during pregnancy to prevent RSV in infants. Researchers will compare health outcomes of babies born to vaccinated mothers versus unvaccinated mothers using electronic medical records. The goal is to see if the vacc…

This massive study is testing whether the Abrysvo RSV vaccine can prevent hospitalizations due to RSV in adults aged 18 and older. Half of the 690,000 participants will receive the vaccine, while the other half will not. Researchers will track how many in each group end up hospit…

This study tests two new vaccines (SCB-1022 and SCB-1033) designed to protect against RSV, human metapneumovirus, and parainfluenza virus. About 612 healthy adults aged 60-85 will receive either a vaccine or a placebo. The main goal is to check safety and how well the vaccines tr…

This early-stage study tests a new vaccine called VXB-241 in healthy adults aged 60-83, with a smaller group of younger adults (18-40) first. The vaccine is designed to protect against two viruses that can cause serious lung infections: RSV and HMPV. Researchers will check how sa…

This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and how well it triggers…

This study checks how well the ABRYSVO® vaccine protects infants from severe RSV when given to pregnant women. Researchers will look at hospital records from Argentina and Uruguay over several RSV seasons. The goal is to see if the vaccine reduces hospitalizations and severe illn…

This study reviews medical records to see how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV lung infections in adults 60 and older. Researchers will analyze existing health data from routine doctor visits over several years. No new treatments or active participat…

This phase 3 trial is testing a non-live, adjuvanted RSV vaccine (Arexvy) in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants…

This early-stage study tests an experimental mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy volunteers, split into two age groups (18-45 and 60+), will receive either the vaccine or a pla…

This early-stage trial is testing a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune respo…

This study tests a new vaccine called LYB005 against RSV, a virus that can cause serious lung infections in older adults. About 700 volunteers aged 60 and older will receive either the vaccine or a placebo. Researchers will check how well the vaccine boosts the immune system and …

This study looks at how well the ABRYSVO vaccine, given to pregnant women, protects their babies from RSV, a leading cause of severe lung infections in infants. Researchers will analyze medical records of infants up to 6 months old in western Pennsylvania over several RSV seasons…

This study is checking the safety of the Abrysvo RSV vaccine in adults aged 60 and older in everyday medical practice in Japan. About 1100 people who get the vaccine will be watched for side effects for 28 days. The goal is to confirm the vaccine is safe for older adults.

This Phase 3 study tests whether a single dose of Pfizer's RSV vaccine (RSVpreF) can prevent lower respiratory tract illness caused by RSV in adults aged 60 and older. Over 38,800 participants across multiple countries received either the vaccine or a placebo. The study also look…

This phase 2 trial is testing a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive either a low or high dose of the vaccine or a placebo. The study measures how well the vaccine boosts antibodies…

This early-stage trial tests a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV). Around 96 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.

This study tests a new mRNA vaccine designed to protect adults aged 60 and older from two viruses that can cause serious lung infections: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). About 1,530 participants will receive either the vaccine or a placebo to c…

This study tests a new mRNA vaccine called IN006 against respiratory syncytial virus (RSV) in 500 healthy adults aged 60 and older. The vaccine is given as two different doses, with a booster after 12 or 24 months. Researchers will monitor safety and measure immune responses like…

This study looks at the real-world effectiveness of the RSV vaccine Abrysvo in adults. Researchers will analyze health records from over 290,000 people to compare those who got the vaccine with those who did not. The goal is to see if the vaccine reduces hospitalizations and othe…

This study tests the safety of palivizumab, a drug given as monthly injections, in infants under 24 months who are at high risk for severe RSV disease. About 138 children born prematurely or with certain lung or heart conditions will receive up to 5 doses. Researchers will monito…

This study will check how well two RSV prevention methods work in real life: a vaccine given to pregnant women and an antibody shot given to newborns. Researchers will follow about 1,100 infants under 6 months old who are hospitalized with severe respiratory infections in Bogotá,…

This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and young children. About 110 infants and toddlers up to 24 months old will receive the medicine as part of their regular care. Researchers will track side effects and how many children ge…

This study compares two methods to prevent RSV, a common virus that can cause serious breathing problems in babies. One method is a vaccine given to pregnant women, which passes protection to the baby before birth. The other is an antibody shot given directly to the newborn. The …

This study checks how well the RSV vaccine (ABRYSVO) works when given to pregnant women to protect their babies from severe RSV illness. Researchers will look at health records of infants hospitalized with breathing problems in Australia. They want to see if vaccinated moms' babi…

Researchers are reviewing medical records from a large hospital network in Buenos Aires to understand what happens to adults with severely weakened immune systems after they catch RSV, influenza, or SARS-CoV-2. The study covers 350 patients and looks at how sick they were at diag…

This study looks at how the RSV vaccine affects the immune system in adults aged 60 and older. Researchers will take blood samples before and after vaccination to find early signs of protection. The goal is to understand why some people respond better than others. 14 volunteers w…

This study follows 300 pregnant women who had respiratory infections to see if RSV can pass from mother to baby before birth. Researchers will test blood from mothers and umbilical cords for RSV antibodies and viruses. Babies will be tracked for up to 4 years to monitor respirato…

This study follows 500 children under 18 who tested positive for flu, RSV, or COVID-19. Each child takes a daily nose swab for 14 days to measure how the virus levels change over time. Researchers also check if family members get sick. The goal is to understand when kids are most…

This study examines medical records of 1,100 children under 18 from hospitals across China who were hospitalized with RSV-positive bronchiolitis or pneumonia between 2017 and 2021. Researchers aim to understand how the disease is diagnosed and treated, and what it costs families …